| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 7.66 | 49.1% | 46.3% |
| Total Income | 7.66 | 49.1% | 46.3% |
| Expenditure | 120.42 | 4.2% | 3.1% |
| PBT | — | ||
| Net Profit | -106.63 | 10.8% | 5.3% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.80 | 1.2% | 18.4% |
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
06 Aug 2026 · 6 Aug, 5:17 pm
Summary
Intellia Therapeutics reported business updates and financial results for the second quarter ended June 30, 2026. The company highlighted positive Phase 3 HAELO clinical trial results for lonvo-z in hereditary angioedema and anticipates FDA BLA acceptance in the second half of 2026 with a potential launch in the first half of 2027. Enrollment has resumed for nex-z Phase 3 trials, and the company ended the quarter with $628 million in cash, sufficient to fund operations into 2028. Collaboration revenue decreased to $7.7 million from $14.2 million year-over-year, while net loss widened slightly to $106.6 million from $101.3 million.
Key Highlights
- 1
Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), showing an 87% reduction in attacks versus placebo.
- 2
The company anticipates FDA acceptance of the BLA for lonvo-z in the second half of 2026, with a potential U.S. launch in the first half of 2027.
- 3
Enrollment has been successfully reinitiated in nex-z Phase 3 clinical trials, with MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in the second half of 2026.
- 4
New genomic insights have enhanced the understanding of nex-z's profile and its potential to deliver clinically meaningful outcomes for patients.
- 5
Intellia Therapeutics ended the second quarter with approximately $628 million in cash, cash equivalents, and marketable securities, expected to fund operations at least into 2028.
- 6
Collaboration revenue was $7.7 million for the second quarter of 2026, a decrease from $14.2 million in the second quarter of 2025, primarily due to a reduction in revenue from Regeneron.
- 7
Net loss for the second quarter of 2026 was $106.6 million, compared to $101.3 million for the second quarter of 2025.
Management Comments
John Leonard
The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema. These data serve as strong validation for in vivo gene editing and lonvo-z’s potential to transform the treatment paradigm for patients who are burdened by this disease. We also resumed enrollment in our Phase 3 clinical trials in ATTR during the second quarter and gained important new genomic insights that enhance our understanding of nex-z’s safety profile and its potential to deliver clinically meaningful outcomes for patients. Underpinned by a recent capital raise that strengthened our balance sheet, we are well positioned to deliver on our research, regulatory, clinical and commercial objectives.
Informational and educational content only. Not investment advice.